Merger (Tables)

12 Months Ended

Dec. 31, 2023

Merger

Schedule of fair values of assets acquired and liabilities

Common stock issued to Morphimmune shareholders	$	72,453
Share-based equity awards allocated to consideration paid		14,708
Transaction costs		792
Consideration paid	$	87,953
Assets acquired:
Cash and cash equivalents	$	10,068
Prepaid expenses and other current assets		191
Property and equipment		646
In-process research and development		80,802
Total assets acquired	$	91,707
Liabilities assumed:
Accounts payable	$	1,147
Accrued expenses		2,607
Total liabilities assumed	$	3,754
Net assets acquired	$	87,953